DBV Technologies S.A. (DBVT)
DBVT Stock Price Chart
Explore DBV Technologies S.A. interactive price chart. Choose custom timeframes to analyze DBVT price movements and trends.
DBVT Company Profile
Discover essential business fundamentals and corporate details for DBV Technologies S.A. (DBVT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Oct 2014
Employees
106.00
Website
https://www.dbv-technologies.comCEO
Daniel Tassé
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBVT Financial Timeline
Browse a chronological timeline of DBV Technologies S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Mar 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$1.45.
Earnings released on 29 Jul 2025
EPS came in at -$1.55 falling short of the estimated -$0.21 by -638.10%, while revenue for the quarter reached $1.74M , beating expectations by +128.53%.
Earnings released on 30 Apr 2025
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%, while revenue for the quarter reached $906.41K , beating expectations by +81.28%.
Earnings released on 27 Mar 2025
EPS came in at -$1.20 surpassing the estimated -$2.00 by +40.00%, while revenue for the quarter reached $553.10K , beating expectations by +19.52%.
Stock split effective on 29 Nov 2024
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 Nov 2024
EPS came in at -$0.80 surpassing the estimated -$1.90 by +57.89%, while revenue for the quarter reached $1.18M , beating expectations by +13.01%.
Earnings released on 30 Jul 2024
EPS came in at -$1.70 falling short of the estimated -$1.30 by -30.77%, while revenue for the quarter reached $1.25M , beating expectations by +9.50%.
Stock split effective on 7 Jun 2024
Shares were split 1 : 2 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 May 2024
EPS came in at -$1.40 surpassing the estimated -$2.20 by +36.36%, while revenue for the quarter reached $1.51M , beating expectations by +9.53%.
Earnings released on 7 Mar 2024
EPS came in at -$0.12 surpassing the estimated -$0.32 by +62.50%, while revenue for the quarter reached $2.44M , missing expectations by -4.61%.
Earnings released on 31 Oct 2023
EPS came in at -$0.18 surpassing the estimated -$0.30 by +40.00%, while revenue for the quarter reached $2.53M , missing expectations by -8.33%.
Earnings released on 31 Jul 2023
EPS came in at -$0.26 matching the estimated -$0.26, while revenue for the quarter reached $2.50M , beating expectations by +25.27%.
Earnings released on 4 May 2023
EPS came in at -$0.22 surpassing the estimated -$0.50 by +56.00%, while revenue for the quarter reached $2.39M , missing expectations by -9.55%.
Earnings released on 2 Mar 2023
EPS came in at -$2.30 matching the estimated -$2.30, while revenue for the quarter reached -$1.40M , missing expectations by -193.34%.
Earnings released on 3 Nov 2022
EPS came in at -$0.18 surpassing the estimated -$0.32 by +43.75%, while revenue for the quarter reached $2.03M , missing expectations by -19.17%.
Earnings released on 1 Aug 2022
EPS came in at -$1.80 falling short of the estimated -$1.70 by -5.88%, while revenue for the quarter reached $1.60M , missing expectations by -6.22%.
Earnings released on 2 May 2022
EPS came in at -$1.50 surpassing the estimated -$4.70 by +68.09%, while revenue for the quarter reached $2.82M , beating expectations by +12.48%.
Earnings released on 3 Mar 2022
EPS came in at -$0.26 surpassing the estimated -$0.64 by +59.38%, while revenue for the quarter reached $2.59M , beating expectations by +7.07%.
Earnings released on 26 Oct 2021
EPS came in at -$2.20 surpassing the estimated -$2.90 by +24.14%, while revenue for the quarter reached $1.54M , missing expectations by -39.94%.
Earnings released on 2 Aug 2021
EPS came in at -$2.80 surpassing the estimated -$6.40 by +56.25%, while revenue for the quarter reached $1.77M .
Earnings released on 3 May 2021
EPS came in at -$2.70 surpassing the estimated -$3.90 by +30.77%, while revenue for the quarter reached $3.46M .
Earnings released on 11 Mar 2021
EPS came in at -$0.88 surpassing the estimated -$1.22 by +27.59%, while revenue for the quarter reached -$1.49M .
Earnings released on 30 Oct 2020
EPS came in at -$0.66 falling short of the estimated -$0.30 by -120.89%, while revenue for the quarter reached $4.88M .
DBVT Stock Performance
Access detailed DBVT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.